Literature DB >> 11564966

Terbinafine-induced hepatic dysfunction.

W M Chambers1, A Millar, S Jain, A K Burroughs.   

Abstract

A 41-year-old man developed severe hepatic dysfunction following a 3.5-week course of terbinafine (250 mg/day). He suffered marked pruritus, jaundice, malaise, anorexia and loin pain. Serum bilirubin rose to a peak value of 718 micromol/l with alkaline phosphatase at 569 U/l, alanine aminotransferase at 90 U/l, aspartate aminotransferase at 63 U/l and a prolonged prothrombin time of 21 s, unresponsive to vitamin K. Transjugular liver biopsy showed canalicular cholestasis consistent with a drug reaction. Symptoms resolved 11 months after drug cessation, with liver function tests returning to normal values after 15 months. This case represents the most severe cholestatic reaction reported to date, resulting in patient recovery without liver transplantation. A comprehensive literature review is provided.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564966     DOI: 10.1097/00042737-200109000-00021

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  4 in total

Review 1.  Systematic review of severe acute liver injury caused by terbinafine.

Authors:  Jun Yan; Xiaolin Wang; Shengli Chen
Journal:  Int J Clin Pharm       Date:  2014-07-02

2.  A curious case of cholestasis: oral terbinafine associated with cholestatic jaundice and subsequent erythema nodosum.

Authors:  Kartik Kumar; Anna Gill; Rachelle Shafei; Janine L Wright
Journal:  BMJ Case Rep       Date:  2014-12-05

3.  Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers.

Authors:  R H Khengar; S A Jones; R B Turner; B Forbes; M B Brown
Journal:  Pharm Res       Date:  2007-07-31       Impact factor: 4.200

4.  An investigation of how fungal infection influences drug penetration through onychomycosis patient's nail plates.

Authors:  W J McAuley; S A Jones; M J Traynor; S Guesné; S Murdan; M B Brown
Journal:  Eur J Pharm Biopharm       Date:  2016-03-08       Impact factor: 5.571

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.